1 	|BT| (NP (NP (PP (IN As) (NP (NN result))) (, ,) (NP (NP (NN CDCA1) (JJ novel) (NN cancer-testis) (NN antigen) (JJ overexpressed) (NN LC)) (, ,) (NP (JJ cholangiocellular) (NN cancer)) (, ,) (NP (JJ urinary) (NN bladder) (NN cancer) (JJ renal) (NN cell) (NN cancer)) (, ,) (NP (NN CDCA1)) (VP (MD may) (ADVP (RB therefore)) (NP (JJ ideal) (NN TAA) (JJ useful) (NN diagnosis) (NN immunotherapy) (NN cancer)))))) |ET| |BS|259:D12.776.395.240.150.500 263:E01 295:C04.557.470.200.025.390 296:D02.065.064.786 297:C14.907.055.239.125 298:E02.095.465.425 299:D23.050|ES| 2:1 18:1 19:1 25:1 94:1 101:1 168:1 218:1 491:1 564:1 891:1 922:1 1028:1 1029:1 1030:1 1031:1 1032:1 1033:1 1034:1 1035:1 1036:1 1037:1 1038:1
1 	|BT| (S (PP (IN As) (NP (NP (NN Bim) (NN expression) (JJ critical) (NN biomarker) (NN response)) (NP (JJ many) (VBN targeted) (NN therapy)))) (, ,) (NP (NN PTK6) (NN inhibition)) (VP (MD may) (VP (VB offer) (NP (NP (JJ therapeutic) (NN approach)) (VP (VBG treating) (NP (NN patient) (NN Her2) (VBN targeted) (JJ therapy-resistant) (NN breast) (NN cancer))))))) |ET| |BS|43:F01.145.544 50:M01.643 52:E02 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 158:D23.101|ES| 2:1 16:1 18:1 19:1 23:1 103:1 115:1 120:1 130:1 168:1 491:1 494:1 541:1 825:1 885:1 911:1 1039:1 1040:1 1041:1 1042:1 1043:1 1044:1 1045:1
1 	|BT| (S (NP (NN BACKGROUND) (: :)) (NP (NN MUC4) (VBN cloned) (JJ tracheobronchial) (NN mucosa) (NN cDNA)) (ADVP (RB reportedly)) (ADVP (RB highly)) (VP (VBN expressed) (NP (NP (JJ human) (NN malignancy)) (, ,) (PP (VBG including) (NP (NN lung) (NN carcinoma)))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 182:A04.411 265:C04.557.470.200 300:D13.444.308.497.220 301:A11.251.353 302:A10.615.550|ES| 2:1 6:1 19:1 36:1 49:1 104:1 304:1 328:1 561:1 579:1 626:1 1046:1 1047:1 1048:1 1049:1 1050:1 1051:1
1 	|BT| (NP (NP (NP (JJ Basal) (NN cell) (NN carcinosarcoma) (NN PTCH1) (NN mutation)) (NP (JJ epithelial) (JJ sarcomatoid) (JJ primary) (NN tumor) (NN component) (JJ sarcomatoid) (NN metastasis)))) |ET| |BS|8:C04 18:G05.365.590 41:A11 113:C04.697.650 303:C04.557.450.795 304:C04.557.435.290|ES| 7:1 19:1 34:1 94:1 127:1 344:1 806:1 1021:1 1052:1 1053:1 1054:1 1055:1
1 	|BT| (S (VP (JJ BCL2-like) (NP (NP (CD 11) (NN intron) (CD 2) (NN deletion) (NN polymorphism)) (VP (VBN associated) (NP (JJ non-small) (NN cell) (NN lung) (NN cancer) (NN risk) (NN prognosis)))))) |ET| |BS|54:G05.360.340.024.340.375.500.791.150 61:E05.318.740.600.800 110:C04.588.894.797.520.109.220.249 163:E01.789 305:G05.360.340.024.220.400 306:G05.355.600.800 307:G05.365.795|ES| 18:1 19:1 94:1 148:1 169:1 171:1 328:1 544:1 694:1 1056:1 1057:1 1058:1 1059:1 1060:1
1 	|BT| (S (NP (NN CD133)) (VP (VBN considered) (S (NP (NP (JJ stem-like) (NN cell) (NN marker) (NN cancer)) (PP (VBG including) (NP (NP (JJ gastric) (NN cancer)) (, ,) (NP (NP (NN Notch1) (NN signaling)) (VP (VBN known) (NP (NN play) (JJ important) (NN role) (NN maintenance) (NN differentiation) (JJ stem-like) (NN cell)))))))))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 69:G02.111.087.800 74:G04.299.151 79:I03.450.642.693 158:D23.101 188:N02.628 308:A11.872 309:A18.024.937|ES| 2:1 18:1 19:1 31:1 86:1 94:1 195:1 215:1 238:1 534:1 556:1 561:1 651:1 652:1 902:1 1061:1 1062:1 1063:1
1 	|BT| (NP (NP (NN Characterization) (JJ tumor-suppressive) (NN function) (NN SOX6) (JJ human) (NN esophageal) (JJ squamous) (NN cell) (NN carcinoma))) |ET| |BS|8:C04 55:B01.050.150.900.649.801.400.112.400.400|ES| 19:1 33:1 36:1 94:1 177:1 304:1 1064:1 1065:1 1066:1 1067:1
1 	|BT| (S (NP (NN Chemokine) (NN gene) (NN expression) (JJ clonal) (NN analysis) (NN B) (NN cell) (NN tissue)) (VP (VBN involved) (NP (JJ lymphoid) (JJ interstitial) (NN pneumonitis) (JJ HIV-infected) (JJ pediatric) (NN patient)))) |ET| |BS|50:M01.643 98:A10 155:G05.355.310 301:A11.251.353 310:A11.063.438 311:B04.820.650.589.650.350 312:C02.782.815.616.400.500 313:D12.644.276.374.200 314:C02.782.815.616.400 315:H02.403.670|ES| 9:1 19:1 94:1 115:1 120:1 272:1 661:1 763:1 774:1 1068:1 1069:1 1070:1 1071:1 1072:1 1073:1 1074:1
1 	|BT| (S (NP (JJ Chromosomal) (NN analysis)) (VP (VBD revealed) (SBAR (S (NP (NP (JJ close) (JJ genetic) (NN relationship) (NN papillary) (JJ urothelial) (JJ choriocarcinomatous) (NN tumor) (NN component)) (, ,) (VP (VBG documenting) (NP (JJ first) (NN time) (NN choriocarcinoma) (JJ renal) (NN pelvis)))) (VP (VBP result) (NP (JJ clonal) (NN evolution) (JJ urothelial) (NN carcinoma) (NN acquisition) (JJ trophoblastic) (NN differentiation))))))) |ET| |BS|8:C04 74:G04.299.151 149:G05.360.340.024.340.364.875.890 289:A11.284.187 316:C04.557.465.955.207 317:C04.557.470.200.430 318:A05.810.453.537 319:A11.382.992 320:G04.299.350 321:A10.272.850 322:G01.910|ES| 2:1 7:1 19:1 101:1 215:1 223:1 275:1 304:1 661:1 816:1 864:1 922:1 1021:1 1069:1 1075:1 1076:1 1077:1 1078:1 1079:1 1080:1 1081:1 1082:1 1083:1 1084:1 1085:1 1086:1
1 	|BT| (S (VP (VBG Combining) (NP (NN kallistatin) (NN gene) (NN therapy) (NN meloxicam) (NN treat) (JJ hepatocellular) (NN carcinoma) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 104:C04.557.470.200.025.255|ES| 9:1 19:1 52:1 130:1 303:1 304:1 1087:1 1088:1 1089:1 1090:1
1 	|BT| (S (NP (NP (JJ Comparative) (NN analysis) (NN expression) (JJ Pathogenesis-Related) (CD 1) (-LRB- -LRB-) (NN P6) (-RRB- -RRB-) (NN gene)) (, ,) (NP (NN marker))) (VP (VBD induced) (NP (NP (NN resistance) (NN pathogen)) (, ,) (NP (NP (JJ various) (NN tissue) (NN tomato) (NN plant)) (VP (VBN treated) (NP (NN CF) (NN root)))) (NP (VBD suggested) (NN B))))) |ET| |BS|6:G05.360.340.024.340 52:E02 98:A10 158:D23.101 323:B01.650.940.800.575.100.905.322 324:B01.650.940.800.575.100.905.322 325:Z01.058.290.100.140 326:A18.400 327:G06.930 328:B01.650|ES| 2:1 9:1 10:1 14:1 19:1 98:1 115:1 272:1 412:1 534:1 661:1 763:1 925:1 1091:1 1092:1 1093:1 1094:1 1095:1 1096:1 1097:1 1098:1 1099:1 1100:1 1101:1
1 	|BT| (S (NP (NP (NP (JJ Comparative) (NN analysis) (NN expression) (JJ Pathogenesis-Related) (CD 1) (-LRB- -LRB-) (NN P6) (-RRB- -RRB-) (NN gene)) (, ,) (NP (NN marker))) (VP (VBD induced) (NP (NP (NN resistance) (NN pathogen)) (, ,) (NP (NP (JJ various) (NN tissue) (NN tomato) (NN plant)) (VP (VBN treated) (NP (NN CF) (NN root))))))) (VP (VBD suggested) (SBAR (S (NP (NNP B.) (JJ thuringiensis-induced) (NN defense) (NN system)) (VP (VBD activated) (NP (NP (NN leaf)) (, ,) (NP (NN stem)) (, ,) (NP (JJ main) (NN root) (NN tissue)) (, ,) (NP (JJ lateral) (NN root) (NN tissue)))))))) |ET| |BS|6:G05.360.340.024.340 52:E02 98:A10 158:D23.101 309:A18.024.937 323:B01.650.940.800.575.100.905.322 324:B01.650.940.800.575.100.905.322 325:Z01.058.290.100.140 326:A18.400 327:G06.930 328:B01.650 329:A14.549.167.900.750 330:A18.024.812|ES| 2:1 9:1 10:1 14:1 19:1 98:1 115:1 163:1 272:1 412:1 534:1 593:1 661:1 925:1 1091:1 1092:1 1093:1 1094:1 1095:1 1096:1 1097:1 1098:1 1099:1 1100:1 1101:1 1102:1 1103:1 1104:1 1105:1 1106:1 1107:1 1108:1
1 	|BT| (S (NP (NP (NNS CONCLUSIONS) (: :)) (S (VP (NN DCAMKL-1) (NP (JJ negative) (NN regulator) (NN let-7a) (NN miRNA) (NN biogenesis) (JJ intestinal) (NN stem) (JJ colorectal) (NN cancer) (NN cell)))) (: ;)) (VP (MD could) (VP (VB represent) (NP (JJ novel) (NN target) (JJ anti-cancer) (NN stem) (JJ cell-based) (NN strategy))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 20:G03.495 41:A11 47:A03.556.124 184:D13.150.650.319 259:D12.776.395.240.150.500 309:A18.024.937 331:G16.595 332:A11.872.650 333:D01.045|ES| 17:1 18:1 19:1 94:1 104:1 109:1 160:1 217:1 235:1 239:1 449:1 799:1 840:1 891:1 908:1 1106:1 1109:1 1110:1 1111:1 1112:1 1113:1 1114:1
1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (NN Expression) (NN ra) (NN protein) (NN type) (CD II) (JJ alveolar) (NNS pneumocytes) (NN mutation) (NN codon) (CD 12) (JJ K-ras) (NN gene) (NN lung) (NN tissue)) (VP (MD may) (VP (VB contribute) (NP (NN induction) (NN lung) (NN carcinoma) (NN patient) (NN IPF)))))) |ET| |BS|18:G05.365.590 50:M01.643 98:A10 182:A04.411 265:C04.557.470.200 276:C08.381.483.487.500 334:D08.811.277.040.330.300.400.500 335:D13.444.735.544.355 336:A04.411.715.512 337:C08.381.765|ES| 4:1 9:1 19:1 34:1 104:1 120:1 239:1 272:1 304:1 316:1 328:1 450:1 491:1 543:1 736:1 1115:1 1116:1 1117:1 1118:1 1119:1 1120:1 1121:1 1122:1
1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (NP (NP (NN Jab1) (NN expression)) (, ,) (NP (ADVP (RB well)) (NP (NP (NN p27)) (PRN (-LRB- -LRB-) (NP (NN Kip1)) (-RRB- -RRB-))) (NN upregulation)) (, ,) (NP (JJ evident) (JJ early) (NN stage) (NN hepatocarcinogenesis)) (, ,) (S (VP (VBG suggesting) (SBAR (S (NP (NN Jab1)) (VP (MD could) (NP (JJ diagnostic) (NN marker) (NN treatment) (NN target) (JJ precancerous) (NN lesion) (JJ early) (NNS HCCs))))))))) |ET| |BS|52:E02 104:C04.557.470.200.025.255 158:D23.101 249:G05.355.315.800 263:E01 338:D12.644.360.225.600 339:G02.111.087.880 340:C17.800.229.400 341:C04.834|ES| 2:1 10:1 14:1 19:1 104:1 115:1 160:1 239:1 534:1 546:1 787:1 900:1 903:1 908:1 1009:1 1123:1 1124:1 1125:1 1126:1 1127:1 1128:1 1129:1 1130:1 1131:1 1132:1
1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (NN Reduction) (NN ING1b) (NN gene) (NN expression)) (VP (VBN associated) (VP (VBD reduced) (NP (NN p21) (NN bax) (NN gene) (NN expression) (NNS NSCLCs)))))) |ET| |BS|110:C04.588.894.797.520.109.220.249 155:G05.355.310 342:D12.644.360.075.718.400|ES| 9:1 19:1 104:1 115:1 169:1 239:1 452:1 1133:1 1134:1 1135:1 1136:1 1137:1
1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (DT The) (CD two) (NN library)) (ADVP (RB differentially)) (VP (VBD expressed) (SBAR (S (NP (NN gene)) (VP (MD may) (VP (VB provide) (NP (NN basis) (JJ new) (NN insight) (NN clue) (NN finding) (JJ novel) (NN lung) (JJ cancer-related) (NN gene)))))))) (: ;) (S (NP (JJ several) (NN gene)) (ADVP (RB newly)) (VP (VBD found) (NP (NP (NN lung) (NN cancer) (NN ERGIC3)) (VP (VBG seeming) (NP (JJ novel) (NN lung) (JJ cancer-related) (NN gene))))))) |ET| |BS|9:G05.360.340.024.340.375.500 182:A04.411 259:D12.776.395.240.150.500 275:C23.888 343:G05.360.325 344:M01.438|ES| 6:1 9:1 18:1 19:1 37:1 104:1 217:1 239:1 262:1 328:1 491:1 691:1 711:1 712:1 891:1 927:1 933:1 1138:1 1139:1 1140:1 1141:1 1142:1 1143:1 1144:1 1145:1 1146:1
1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (NP (NP (DT This) (NN panel)) (SBAR (S (NP (JJ variant-specific) (, ,) (JJ quantitative) (NN RT-PCR) (NN assay)) (VP (VBZ detects) (NP (NP (JJ common) (NN EML4-ALK) (CC +) (JJ variant) (RB well) (NN ALK) (NN gene) (NN expression) (NN level)) (JJ archival) (JJ formalin-fixed) (JJ paraffin-embedded) (NN NSCLC) (NN specimen))))))) |ET| |BS|106:E05.091 110:C04.588.894.797.520.109.220.249 155:G05.355.310 272:E05.393.620.500.725 345:E01.370.225.500.620.720.610 346:E05.393.620.500.706 347:D02.047.407 348:K01.400.152|ES| 2:1 9:1 19:1 104:1 115:1 239:1 249:1 310:1 329:1 510:1 655:1 787:1 807:1 817:1 962:1 990:1 1147:1 1148:1 1149:1 1150:1 1151:1 1152:1 1153:1 1154:1
1 	|BT| (S (NP (NNS CONCLUSIONS)) (: :) (NP (PRP We)) (VP (VBD provided) (NP (JJ first) (NN evidence) (NN SOX6) (JJ novel) (JJ tumor-suppressor) (NN gene) (NN ESCC) (NN development) (JJ potential) (JJ prognostic) (NN marker) (NN ESCC)))) |ET| |BS|149:G05.360.340.024.340.364.875.890 158:D23.101 206:G05.360.340.024.340.375.249 259:D12.776.395.240.150.500|ES| 9:1 19:1 35:1 38:1 104:1 239:1 534:1 816:1 827:1 843:1 884:1 891:1 1065:1 1155:1 1156:1 1157:1
1 	|BT| (S (NP (NN Cyclooxygenase-2) (NN inhibitor)) (VP (VBP down-regulate) (NP (NN osteopontin) (NN Nr4A2-new) (JJ therapeutic) (NN target) (JJ colorectal) (NN cancer)))) |ET| |BS|4:C04.588.274.476.411.307 52:E02 349:D27.505.519.389.310.500 350:D12.644.276.374.625 351:A17.360|ES| 17:1 18:1 19:1 160:1 380:1 541:1 1158:1 1159:1 1160:1 1161:1
1 	|BT| (S (NP (NP (NP (NN DDR2)) (PRN (-LRB- -LRB-) (NP (NN L63V)) (-RRB- -RRB-))) (: ;) (NP (NP (NN TP53)) (PRN (-LRB- -LRB-) (NP (NN L/L)) (-RRB- -RRB-))) (NP (NN mouse))) (VP (VBD developed) (NP (NP (ADJP (RB poorly) (VBN differentiated)) (NN lung) (NN adenocarcinoma) (JJ transgenic) (NN animal)) (VP (VBN analyzed) (NP (NN latency) (CD 40) (CD 50) (NN week) (NN median) (NN survival) (CD 67.5) (NN week)))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 74:G04.299.151 96:I03.784 352:B01.050.050.136|ES| 10:1 14:1 19:1 46:1 52:1 217:1 255:1 274:1 285:1 328:1 368:1 582:1 783:1 1018:1 1162:1 1163:1 1164:1 1165:1 1166:1 1167:1 1168:1 1169:1 1170:1 1171:1
1 	|BT| (S (NP (NN DEP) (NN domain)) (VP (VP (VBG containing) (NP (CD 1) (-LRB- -LRB-) (NN DEPDC1) (-RRB- -RRB-))) (SBAR (S (NP (ADJP (RB newly) (VBN identified)) (NP (JJ cancer-related) (NN cell) (NN cycle)) (JJ related) (NN gene)) (VP (VBD demonstrated) (NP (JJ novel) (JJ therapeutic) (NN target) (NN bladder) (NN cancer))))))) |ET| |BS|6:G05.360.340.024.340 52:E02 259:D12.776.395.240.150.500 353:G04.299.134|ES| 9:1 10:1 14:1 18:1 19:1 94:1 98:1 160:1 286:1 419:1 541:1 564:1 601:1 623:1 891:1 1143:1 1144:1 1172:1 1173:1 1174:1 1175:1
1 	|BT| (S (NP (NN DEPDC1)) (VP (VBD required) (NP (NN cell) (NN cycle) (NN progression) (NN motility) (JJ nasopharyngeal) (NN carcinoma)))) |ET| |BS|16:C23.550.291.656 353:G04.299.134|ES| 19:1 48:1 94:1 304:1 601:1 1174:1 1176:1 1177:1 1178:1
1 	|BT| (S (NP (NN Detection)) (VP (VBN methylated) (S (NP (NN BCL6B)) (VP (MD may) (VP (VB serve) (NP (JJ independent) (NN biomarker) (NN prognosis) (NN GC))))))) |ET| |BS|36:G02.111.087.029.538 158:D23.101 163:E01.789|ES| 19:1 491:1 532:1 544:1 554:1 883:1 885:1 1179:1 1180:1 1181:1
1 	|BT| (S (NP (NN Detection)) (VP (VBN methylated) (S (NP (NN PAX5)) (VP (VBD utilized) (NP (JJ independent) (JJ prognostic) (NN factor) (NN GC)))))) |ET| |BS|36:G02.111.087.029.538 243:D12.776.260.645.500|ES| 19:1 185:1 554:1 846:1 883:1 884:1 1179:1 1180:1 1182:1
1 	|BT| (S (NP (NP (NN Detection)) (VP (VBN methylated) (NP (NN TBX5)))) (VP (MD may) (VP (VB serve) (NP (JJ potential) (NN biomarker) (NN prognosis) (NN malignancy))))) |ET| |BS|36:G02.111.087.029.538 158:D23.101 163:E01.789|ES| 19:1 49:1 491:1 532:1 544:1 827:1 885:1 1179:1 1180:1 1183:1
1 	|BT| (S (NP (NN Detection) (NN TFPI2) (NN methylation) (NN stool) (NN DNA)) (VP (MD may) (VP (VB act) (NP (JJ useful) (NN adjunct) (JJ noninvasive) (NN strategy) (NN screening) (NNS CRCs) (NN future))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 36:G02.111.087.029.538 81:E02.095.465.425.400.330.050.400 198:D13.444.308 354:I01.320 355:A12.459|ES| 19:1 81:1 246:1 491:1 666:1 1036:1 1114:1 1179:1 1184:1 1185:1 1186:1 1187:1 1188:1 1189:1 1190:1
1 	|BT| (NP (NP (NP (NN DLGAP5) (NN overexpression) (JJ evident) (CD 25) (NN %)) (PRN (-LRB- -LRB-) (NP (QP (CD 22) (CD 88))) (-RRB- -RRB-))) (NP (NP (NNP HCC) (NN specimen)) (PP (IN without) (NP (NN AFP) (NN expression)))) (, ,) (S (VP (VBG suggesting) (SBAR (S (NP (NN DLGAP5)) (VP (MD may) (NP (JJ novel) (NN biomarker) (NN HCC) (NN pathogenesis)))))))) |ET| |BS|104:C04.557.470.200.025.255 158:D23.101 259:D12.776.395.240.150.500|ES| 2:1 10:1 14:1 19:1 115:1 152:1 369:1 441:1 491:1 501:1 885:1 891:1 1009:1 1127:1 1154:1 1191:1 1192:1 1193:1 1194:1 1195:1 1196:1
1 	|BT| (NP (NP (JJ Dual) (JJ therapeutic) (NN effect) (NN interferon-alpha) (NN gene) (NN therapy) (NN rat) (JJ hepatocellular) (NN carcinoma) (NN model) (NN liver) (NN cirrhosis))) |ET| |BS|104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 356:D12.644.276.374.440.890.250 357:C06.552.630|ES| 9:1 19:1 72:1 75:1 130:1 303:1 304:1 541:1 836:1 849:1 1197:1 1198:1 1199:1
1 	|BT| (NP (NP (NN EGFR) (NN gene) (NN mutation) (NN ALK) (NN gene) (NN fusion) (JJ well-characterized) (JJ molecular) (NN target) (NN NSCLC))) |ET| |BS|18:G05.365.590 110:C04.588.894.797.520.109.220.249 358:G05.360.340.024.340.375.500.791.295.300 359:G05.355.760.385|ES| 9:1 19:1 34:1 160:1 161:1 187:1 329:1 936:1 962:1 1200:1
1 	|BT| (NP (NP (JJ Epigenetic) (NN dysregulation) (JJ leukaemic) (NN HOX) (NN code) (JJ MLL-rearranged) (NN leukaemia) (NN mouse) (NN model))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 360:N04.452.758.708.200.400.500 361:C04.557.337|ES| 19:1 52:1 72:1 1201:1 1202:1 1203:1 1204:1 1205:1 1206:1 1207:1
1 	|BT| (S (NP (NN Evaluation) (NN RB) (NN status)) (VP (MD may) (NP (JJ useful) (JJ prognostic) (NN factor) (JJ human) (NN HCC)))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 104:C04.557.470.200.025.255 225:E05.337|ES| 19:1 36:1 185:1 416:1 441:1 491:1 884:1 1036:1 1208:1 1209:1
1 	|BT| (S (NP (NN Expression) (NN DRD2)) (VP (VBZ Is) (SBAR (S (NP (VBN Increased) (JJ Human) (JJ Pancreatic) (JJ Ductal) (NN Adenocarcinoma) (NNS Inhibitors)) (VP (VBP Slow) (NP (NN Tumor) (NN Growth) (NNS Mice))))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 55:B01.050.150.900.649.801.400.112.400.400 362:D12.776.543.750.069.300.400.500 363:C04.557.470.200.025.232.750 364:D27.505.696.377.450|ES| 19:1 316:1 444:1 583:1 1210:1 1211:1 1212:1 1213:1 1214:1 1215:1 1216:1 1217:1 1218:1 1219:1
1 	|BT| (S (NP (NP (NP (CD Fifty-four)) (PRN (-LRB- -LRB-) (NP (CD 73) (NN %)) (-RRB- -RRB-))) (NP (NP (CD 74) (NN lesion) (NNS metaplasias) (JJ bronchiolar) (NN epithelium)) (VP (VBN obtained) (NP (NP (JJ IPF) (NN patient) (NN lung) (NN carcinoma) (CD 8)) (PRN (-LRB- -LRB-) (NP (CD 17) (NN %)) (-RRB- -RRB-))) (NP (NP (CD 46) (NN sample)) (VP (VBN obtained) (NP (NP (JJ IPF) (NN patient)) (PP (IN without) (NP (NN lung) (NN carcinoma))))))))) (VP (VBD showed) (NP (NP (NNP LOH) (NNP FHIT) (NN gene)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJR <) (NP (CD 0.0001)))) (-RRB- -RRB-))))) |ET| |BS|6:G05.360.340.024.340 48:C23.550.589 50:M01.643 62:A10.272 182:A04.411 265:C04.557.470.200 276:C08.381.483.487.500 290:G05.365.590.029.530 337:C08.381.765 365:A04.411.125.500|ES| 9:1 10:1 14:1 19:1 120:1 132:1 173:1 304:1 311:1 312:1 328:1 369:1 575:1 781:1 835:1 930:1 946:1 1004:1 1122:1 1131:1 1195:1 1220:1 1221:1 1222:1 1223:1 1224:1 1225:1 1226:1
1 	|BT| (S (ADVP (RB Furthermore)) (, ,) (NP (NN CD133) (NN DNA) (NN methylation)) (VP (VBZ seems) (VP (VBP constitute) (SBAR (S (NP (JJ abnormal) (NN promoter) (NN signature)) (VP (VBD found) (NP (NP (JJ normal) (NN brain) (NN colon)) (VP (VBN cultured) (NP (JJ primary) (NN tumor)))))))))) |ET| |BS|8:C04 30:Z01.058.290.190.800 31:D08.811.520.224.800 46:A03.556.124.526.356 366:G02.111.087.029.538.161 367:A08.186.211|ES| 2:1 7:1 19:1 37:1 81:1 83:1 113:1 118:1 334:1 344:1 652:1 666:1 1227:1 1228:1 1229:1 1230:1 1231:1 1232:1
1 	|BT| (S (NP (NNP Gene) (NN amplification) (NN 17q) (JJ chromosomal) (NN region)) (VP (VBN observed) (ADVP (RB frequently)) (NP (NN breast) (NN cancer)))) |ET| |BS|292:Z01 368:C23.550.210.182|ES| 18:1 19:1 23:1 261:1 667:1 698:1 921:1 1002:1 1233:1 1234:1
1 	|BT| (S (NP (JJ Genomic) (NN Sequencing)) (VP (VBZ Identifies) (NP (NN ELF3) (NN Driver) (NNP Ampullary) (NNP Carcinoma)))) |ET| |BS|265:C04.557.470.200 268:H01.158.273.180.350 269:G05.360.340|ES| 19:1 1235:1 1236:1 1237:1 1238:1 1239:1 1240:1 1241:1
1 	|BT| (S (NP (NN HEF1)) (VP (MD may) (VP (VB represent) (NP (NP (JJ attractive) (NN candidate) (NN drug)) (VP (VBG targeting) (NP (NN CRC))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 12:Z01.542.049 369:E02.319.300|ES| 19:1 191:1 245:1 491:1 616:1 799:1 974:1 1242:1 1243:1
1 	|BT| (S (NP (ADJP (RB Here) (VBN investigated)) (NN prevalence) (NN pattern) (NN mutation)) (NP (NP (CD two) (NN gene)) (, ,) (NP (NN Ha-ras) (NN beta-catenin)) (, ,)) (VP (VBN known) (NP (JJ mutational) (NN target) (NN mouse) (NN hepatocarcinogenesis)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 23:D12.776.091.249 60:E05.318.308.985.525.750 216:Z01.107.084.900.425|ES| 2:1 9:1 19:1 34:1 52:1 60:1 160:1 179:1 260:1 400:1 403:1 556:1 747:1 900:1 933:1 1244:1
1 	|BT| (S (ADVP (RB Here)) (, ,) (NP (VBD generated) (NN mouse) (NN model) (NN lung) (NN adenocarcinoma)) (VP (VBN driven) (NP (NP (NN mutation) (NN discoidin) (NN domain) (NN receptor) (CD 2) (-LRB- -LRB-) (NN DDR2) (-RRB- -RRB-) (NN gene)) (JJ combined) (NN loss) (NN TP53)))) |ET| |BS|6:G05.360.340.024.340 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 66:F01.658.293|ES| 2:1 9:1 10:1 14:1 19:1 32:1 34:1 52:1 72:1 73:1 148:1 164:1 186:1 255:1 328:1 400:1 920:1 1018:1 1162:1 1173:1 1245:1
1 	|BT| (S (NP (JJR Higher) (NN frequency) (JJ inactive) (NN TP53) (NN mutation)) (ADVP (RB also)) (VP (VBN seen) (S (NP (NP (NP (JJ advanced) (NN stage) (NN tumour)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJ =) (NP (CD 0.0003)))) (-RRB- -RRB-))) (NN tumour) (JJ poor) (JJ prognostic) (NN feature)) (NP (ADJP (NP (JJ vascular)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJ =) (NP (CD 0.006)))) (-RRB- -RRB-))) (NP (NP (JJ lymphatic) (NN invasion)) (PRN (-LRB- -LRB-) (S (NP (NN P)) (VP (JJ =) (NP (CD 0.002)))) (-RRB- -RRB-))))))) |ET| |BS|8:C04 159:I01.880.735.634 194:G05.355.044.250.750 213:F02.830.816.964 370:A15.382.520.301 371:A07.231|ES| 5:1 10:1 14:1 19:1 34:1 311:1 545:1 581:1 620:1 724:1 884:1 997:1 1011:1 1018:1 1129:1 1246:1 1247:1 1248:1 1249:1 1250:1 1251:1 1252:1 1253:1 1254:1
1 	|BT| (S (ADVP (RB However)) (, ,) (NP (NN mutation) (NN exon) (CD 3) (NN beta-catenin) (NN gene)) (VP (VBD detected) (SBAR (S (NP (CD one) (NN tumour)) (VP (VBD expressed) (NP (JJ nuclear) (NN beta-catenin) (JJ lining) (JJ polygonal) (NN component))))))) |ET| |BS|6:G05.360.340.024.340 8:C04 18:G05.365.590 23:D12.776.091.249 372:G05.360.340.024.340.137.232|ES| 2:1 6:1 9:1 19:1 34:1 60:1 433:1 862:1 1007:1 1010:1 1011:1 1021:1 1255:1 1256:1 1257:1 1258:1
1 	|BT| (S (NP (NN HOX) (NN gene)) (ADVP (RB frequently)) (VP (VBN dysregulated) (NP (NP (JJ human) (NN leukaemia) (NN gene) (NN rearrangement) (JJ mixed) (NN lineage) (NN leukaemia)) (PRN (-LRB- -LRB-) (NP (NN MLL)) (-RRB- -RRB-))) (NP (NN partner) (NN gene)))) |ET| |BS|6:G05.360.340.024.340 55:B01.050.150.900.649.801.400.112.400.400 229:G05.360.340.024.340.230.500 361:C04.557.337 373:G05.355.330|ES| 9:1 10:1 14:1 19:1 36:1 698:1 1204:1 1207:1 1259:1 1260:1 1261:1 1262:1 1263:1 1264:1
1 	|BT| (NP (NP (NP (NN Identification) (NN trophinin) (NN enhancer) (NN cell) (NN invasion) (JJ prognostic) (NN factor)) (JJ early) (NN stage) (NN lung) (NN cancer))) |ET| |BS|41:A11 374:F01.393.446 375:Z01.639.100|ES| 18:1 19:1 94:1 185:1 328:1 620:1 884:1 972:1 1128:1 1129:1 1265:1 1266:1
1 	|BT| (S (NP (NN IHH) (NN SMO)) (VP (MD may) (SBAR (S (NP (JJ useful) (NNS biomarkers) (JJ diffuse) (NN cancer)) (VP (MD may) (VP (VB show) (NP (NN growth) (NN inhibition) (NN Hh) (NN antagonist) (NN cyclopamine)))))))) |ET| |BS|43:F01.145.544 45:G07.700.320.249 376:D23.101.140|ES| 18:1 19:1 102:1 103:1 429:1 491:1 653:1 1036:1 1267:1 1268:1 1269:1 1270:1 1271:1 1272:1
1 	|BT| (FRAG (PP (IN In) (NP (JJ CF-treated) (JJ main) (NN root))) (, ,) (NP (NP (JJ CF-treated) (JJ lateral) (NN root)) (, ,) (NP (NP (NN expression) (JJ several) (JJ salicylic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NNP SA)) (-RRB- -RRB-))) (: -) (S (NP (JJ responsive) (JJ defense-related) (NN gene)) (ADVP (RB specifically)) (VP (VBD induced) (, ,) (SBAR (IN whereas) (S (NP (NP (NP (JJ jasmonic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN JA)) (-RRB- -RRB-))) (: -) (NP (JJ related) (NN gene) (NN expression))) (VP (CC either) (VP (VBD down-regulated) (NP (JJ induced) (NN response) (NN CF)))))))))) |ET| |BS|52:E02 142:I01.880.604 155:G05.355.310 325:Z01.058.290.100.140 326:A18.400 351:A17.360 377:D02.241.223.100.300.595.608|ES| 2:1 9:1 10:1 14:1 19:1 39:1 115:1 244:1 262:1 372:1 412:1 494:1 1100:1 1101:1 1107:1 1108:1 1273:1 1274:1 1275:1 1276:1 1277:1 1278:1 1279:1 1280:1 1281:1 1282:1 1283:1
1 	|BT| (FRAG (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NP (VBN defined) (NN subset) (NN bone) (JJ soft) (NN tissue) (NN tumor)) (, ,) (PP (VBG including) (NP (JJ benign) (NN tumor))) (, ,) (S (NP (NN Akt)) (ADVP (RB frequently)) (VP (VBN overexpressed) (S (VP (VBN activated))))) (, ,) (NP (NP (NNP AKT1/2) (NN copy) (NN number)) (VP (VBN increased))))) |ET| |BS|378:D08.811.913.696.620.682.700.755 379:C04.588.839 380:A02.835.232 381:C04|ES| 2:1 7:1 19:1 25:1 47:1 163:1 244:1 272:1 561:1 646:1 680:1 698:1 963:1 1284:1 1285:1 1286:1 1287:1 1288:1 1289:1 1290:1
1 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (VP (VBP suggest) (SBAR (S (NP (NN change) (NN level) (NN cdk4)) (VP (MD may) (NP (JJ useful) (NN biomarker) (NN detection) (NN HCC))))))) |ET| |BS|104:C04.557.470.200.025.255 158:D23.101|ES| 2:1 19:1 200:1 244:1 249:1 441:1 491:1 796:1 885:1 1023:1 1036:1 1284:1 1291:1
1 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NN WT1)) (VP (VBD expressed) (NP (NP (JJ substantial) (NN proportion) (NN HCC)) (VP (VBG contributing) (NP (NN tumor) (NN progression) (NN resistance) (NN chemotherapy)))) (, ,) (S (VP (VBG suggesting) (SBAR (S (NP (NN WT1)) (VP (MD may) (NP (JJ important) (NN target) (NN HCC) (NN treatment))))))))) |ET| |BS|8:C04 12:Z01.542.049 16:C23.550.291.656 52:E02 104:C04.557.470.200.025.255 151:E02.319 382:C04.557.435.595|ES| 2:1 6:1 7:1 19:1 48:1 160:1 244:1 441:1 491:1 495:1 546:1 902:1 1009:1 1094:1 1284:1 1292:1 1293:1 1294:1 1295:1
1 	|BT| (S (PP (IN In) (NP (NN silico) (NN analysis))) (VP (VBD used) (SBAR (S (NP (NN probe) (NN association) (NN gene) (NN expression) (NN signature) (NN RB) (NN loss) (JJ chromosomal) (NN instability) (NN ability) (NN gene)) (VP (VBD up-regulated) (SBAR (S (NP (NN RB) (NN loss)) (VP (VBP predict) (NP (NN survival) (JJ human) (NN HCC) (NN patient)))))))))) |ET| |BS|6:G05.360.340.024.340 30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 55:B01.050.150.900.649.801.400.112.400.400 96:I03.784 104:C04.557.470.200.025.255 142:I01.880.604 150:Z01.542.248.960 383:C23.550.210.110 384:G02.111.087.847.750 385:F02.784.629.131 386:F02.463.425.069 387:L01.224.160|ES| 9:1 19:1 32:1 36:1 115:1 120:1 244:1 274:1 441:1 476:1 661:1 1002:1 1209:1 1230:1 1296:1 1297:1 1298:1 1299:1 1300:1 1301:1 1302:1
1 	|BT| (S (PP (IN In) (NP (JJ current) (NN study))) (, ,) (VP (VBD found) (S (S (NP (NN EREG) (JJ overexpressed) (NNS NSCLCs)) (VP (VBG harboring) (NP (NNP KRAS)))) (, ,) (NP (NNP BRAF) (NN EGFR) (NN mutation)) (VP (VBN compared) (NP (NNS NSCLCs) (JJ wild-type) (NN KRAS/BRAF/EGFR)))))) |ET| |BS|18:G05.365.590 110:C04.588.894.797.520.109.220.249 278:D08.811.913.696.620.682.700.559.842.374 388:G05.360.340.024.340.375.500.791.550|ES| 2:1 8:1 19:1 25:1 34:1 37:1 50:1 131:1 175:1 187:1 244:1 958:1 1137:1 1303:1 1304:1 1305:1 1306:1
1 	|BT| (UCP (PP (IN In) (NP (JJ present) (NN study) (JJ novel) (JJ metastasis-related) (NN gene))) (, ,) (NP (NP (NP (JJ eukaryotic) (NN initiation) (NN factor) (NN 5A2)) (PRN (-LRB- -LRB-) (NP (NN EIF5A2)) (-RRB- -RRB-))) (, ,) (NP (NP (VBN characterized) (NN role) (NN HCC) (NN metastasis)) (VP (VBG underlying) (NP (JJ molecular) (NN mechanism)))))) |ET| |BS|6:G05.360.340.024.340 15:F01.829.316.616 104:C04.557.470.200.025.255 113:C04.697.650 259:D12.776.395.240.150.500 389:D12.776.835.725.868|ES| 2:1 9:1 10:1 14:1 19:1 31:1 131:1 161:1 162:1 185:1 244:1 435:1 441:1 637:1 806:1 891:1 985:1 1307:1 1308:1 1309:1 1310:1 1311:1
1 	|BT| (NP (NP (NP (VBN Increased) (NN loss) (NN chromosome) (NN 9p21) (NN p16) (NN inactivation)) (NP (JJ primary) (JJ non-small) (NN cell) (NN lung) (NN cancer) (NN smoker)))) |ET| |BS|110:C04.588.894.797.520.109.220.249 203:G05.360.340.024.340.375.249.375 289:A11.284.187|ES| 18:1 19:1 32:1 94:1 328:1 344:1 694:1 1005:1 1212:1 1312:1 1313:1 1314:1 1315:1
1 	|BT| (S (NP (NN ING5)) (VP (VP (VBZ suppresses) (NP (NP (NN proliferation)) (, ,) (NP (NN apoptosis)) (, ,) (NP (NN migration) (NN invasion)))) (, ,) (VP (VBZ induces) (NP (JJ autophagy) (NN differentiation) (JJ gastric) (NN cancer) (NN cell))) (: :) (NP (JJ good) (NN marker) (NN carcinogenesis) (JJ subsequent) (NN progression)))) |ET| |BS|16:C23.550.291.656 33:C04.697.098 39:G04.299.139.160 74:G04.299.151 158:D23.101 390:G04.299.139.399|ES| 2:1 18:1 19:1 48:1 86:1 89:1 94:1 104:1 207:1 214:1 215:1 299:1 514:1 534:1 620:1 686:1 1316:1 1317:1 1318:1 1319:1
1 	|BT| (NP (NP (JJ Irrespective) (NN protein) (NN overexpression)) (, ,) (S (NP (NN HER-2)) (: /) (NP (NP (NN neu) (NN gene) (NN amplification) (JJ rare) (NN lung) (NN cancer) (NN study) (NN prevalence) (JJ clinicopathological) (NN implication) (JJ early) (NN stage) (JJ non-small) (NN cell) (NN lung) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN NCSLC)) (-RRB- -RRB-))) (NP (NP (JJ neuroendocrine) (NN tumour)) (PRN (-LRB- -LRB-) (NP (NN NET)) (-RRB- -RRB-))) (VP (NN lung) (S (VP (VBG lacking)))))) |ET| |BS|7:D12.776 63:G05.360.340.024.340.375.500.791.295.305 110:C04.588.894.797.520.109.220.249 237:C04.588.894.797.520 391:E05.318.760.500.875 392:G05.355.315.250 393:A06.688|ES| 2:1 4:1 9:1 10:1 14:1 18:1 19:1 85:1 94:1 131:1 152:1 179:1 328:1 376:1 694:1 921:1 1011:1 1128:1 1129:1 1320:1 1321:1 1322:1 1323:1 1324:1 1325:1 1326:1
1 	|BT| (S (NP (PRP It)) (ADJP (ADJP (RB likely) (JJ major)) (SBAR (S (NP (NN genotype) (JJ gastric) (NN carcinoma)) (VP (VBD placed) (NP (JJS least) (CD 4) (NN microsatellite) (NN category)) (, ,) (S (ADVP (RB thus)) (VP (VBG allowing) (NP (NP (NN construction) (JJ comprehensive) (JJ genetic) (NN classification)) (JJ useful) (NN prediction) (JJ diverse) (JJ clinical) (NN course))))))))) |ET| |BS|70:A03.556.875.875 265:C04.557.470.200 394:G02.111.570.080.708.800.500 395:L01.100 396:G05.380|ES| 2:1 19:1 84:1 86:1 304:1 319:1 462:1 864:1 1036:1 1327:1 1328:1 1329:1 1330:1 1331:1 1332:1 1333:1 1334:1 1335:1 1336:1 1337:1 1338:1 1339:1 1340:1 1341:1
1 	|BT| (S (NP (PRP It)) (VP (VBD suggested) (SBAR (S (NP (NN ING5) (NN expression)) (VP (MD might) (VP (VP (VBN employed) (S (NP (JJ good) (NN marker) (JJ gastric) (NN carcinogenesis) (JJ subsequent) (NN progression)) (VP (VBG inhibiting) (NP (NN proliferation))))) (, ,) (NP (NP (NN growth)) (, ,) (NP (NN migration)) (, ,) (NP (NN invasion) (NN metastasis))))))))) |ET| |BS|16:C23.550.291.656 33:C04.697.098 45:G07.700.320.249 70:A03.556.875.875 113:C04.697.650 122:C14.280.383 158:D23.101|ES| 2:1 19:1 48:1 86:1 102:1 115:1 207:1 299:1 514:1 534:1 620:1 798:1 806:1 880:1 925:1 1316:1 1318:1 1319:1 1327:1 1342:1
1 	|BT| (S (NP (JJ Knock-down) (NN Prmt1) (JJ insufficient) (JJ reverse) (JJ active) (NN chromatin) (NN status)) (VP (VBN hypomethylated) (NP (NN Hox) (NN locus)) (, ,) (S (VP (VBG suggesting) (S (NP (JJ Prmt1-mediated) (NN histone) (NN arginine) (NN methylation)) (VP (ADVP (RB partially)) (NP (VBN involved) (NP (NN maintenance) (NN Hox) (NN expression) (JJ leukaemic) (NN cell))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 36:G02.111.087.029.538 41:A11 188:N02.628 351:A17.360 397:A11.284.430.106.279.345.190.160.180 398:D12.125.068.050 399:D12.776.660.470|ES| 2:1 19:1 81:1 94:1 115:1 197:1 377:1 416:1 503:1 774:1 939:1 1009:1 1063:1 1203:1 1343:1 1344:1 1345:1 1346:1 1347:1 1348:1 1349:1 1350:1 1351:1
1 	|BT| (S (NP (JJ Knock-down) (NN TnC) (NN gene)) (VP (VBD increased) (NP (NN susceptibility) (JJ DSS-induced) (NN colitis)) (, ,) (S (VP (VBN compared) (S (NP (NP (NN TnC)) (PRN (-LRB- -LRB-) (CC +) (: /) (CC +) (-RRB- -RRB-))) (NP (NNS littermates))))))) |ET| |BS|53:C06.405.205.265 400:E05.393.335.500 401:C23.550.291.687|ES| 2:1 9:1 10:1 14:1 19:1 47:1 50:1 51:1 143:1 1343:1 1352:1 1353:1 1354:1 1355:1
1 	|BT| (NP (NP (S (NP (JJ K-ras) (NN gene) (NN mutation)) (VP (VBZ enhances) (NP (NN motility) (VBN immortalized) (NN airway) (NN cell) (NN lung) (NN adenocarcinoma) (NN cell)) (PP (IN via) (NP (NN Akt) (NN activation)))) (: :)) (NP (JJ possible) (NN contribution) (JJ non-invasive) (NN expansion) (NN lung) (NN adenocarcinoma)))) |ET| |BS|18:G05.365.590 41:A11 378:D08.811.913.696.620.682.700.755|ES| 9:1 19:1 34:1 94:1 104:1 225:1 255:1 328:1 596:1 1121:1 1177:1 1289:1 1356:1 1357:1 1358:1 1359:1 1360:1 1361:1 1362:1
1 	|BT| (S (NP (NNP KRAS) (NN gene) (NN mutation)) (VP (VBN linked) (NP (NP (JJ poor) (NN prognosis) (NN resistance)) (JJ therapeutic) (NP (NP (JJ non-small) (NN cell) (NN lung) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN NSCLC)) (-RRB- -RRB-)))))) |ET| |BS|18:G05.365.590 52:E02 110:C04.588.894.797.520.109.220.249 159:I01.880.735.634 163:E01.789|ES| 9:1 10:1 14:1 18:1 19:1 34:1 94:1 328:1 329:1 541:1 544:1 545:1 694:1 1094:1 1305:1 1363:1
1 	|BT| (NP (NP (NP (JJ K-ras) (NN gene) (JJ mutational) (NN analysis)) (NN support) (JJ monoclonal) (NN origin) (JJ biphasic) (JJ pleomorphic) (NN carcinoma) (NN lung))) |ET| |BS|18:G05.365.590 149:G05.360.340.024.340.364.875.890 182:A04.411 265:C04.557.470.200|ES| 9:1 19:1 304:1 328:1 661:1 1121:1 1244:1 1364:1 1365:1 1366:1 1367:1 1368:1
1 	|BT| (NP (NP (NP (NP (NNP KRAS) (NN mutation) (CD one) (JJ common) (NN driver) (NN mutation) (JJ non-small-cell) (NN lung) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN NSCLC)) (-RRB- -RRB-))) (SBAR (S (NP (NN finding) (JJ druggable) (NN target) (NN molecule)) (VP (VBP inhibit) (NP (JJ oncogenic) (NNP KRAS) (NN signaling) (JJ significant) (NN challenge) (NN NSCLC) (NN therapy))))))) |ET| |BS|18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 69:G02.111.087.800 110:C04.588.894.797.520.109.220.249 122:C14.280.383 275:C23.888 279:D27.888.569.100 388:G05.360.340.024.340.375.500.791.550|ES| 10:1 14:1 18:1 19:1 34:1 130:1 135:1 160:1 180:1 195:1 327:1 328:1 329:1 655:1 927:1 953:1 954:1 1010:1 1305:1 1369:1 1370:1 1371:1
1 	|BT| (S (NP (NNP LOH) (NNP FHIT) (NN locus)) (ADVP (RB frequently)) (VP (VBN found) (PP (IN among) (NP (NN lesion) (NNS metaplasias) (JJ bronchiolar) (NN epithelium) (NN patient) (NN IPF))) (PRN (-LRB- -LSB-) (NP (NP (CD 62) (PRN (-LRB- -LRB-) (NP (CD 52) (NN %)) (-RRB- -RRB-))) (NP (CD 119) (JJ informative) (NN lesion))) (-RRB- -RSB-)))) |ET| |BS|48:C23.550.589 50:M01.643 62:A10.272 276:C08.381.483.487.500 290:G05.365.590.029.530 337:C08.381.765 365:A04.411.125.500|ES| 10:1 14:1 19:1 37:1 120:1 173:1 369:1 377:1 698:1 946:1 1004:1 1122:1 1131:1 1222:1 1223:1 1372:1 1373:1 1374:1 1375:1 1376:1 1377:1 1378:1
1 	|BT| (NP (NP (JJ Mammary) (NN analogue) (JJ secretory) (NN carcinoma) (JJ salivary) (NN gland) (JJ high-grade) (NN transformation)) (: :) (NP (NP (NN report) (ADJP (CD 3) (NN case)) (NN ETV6-NTRK3) (NN gene) (NN fusion) (NN analysis) (NN TP53)) (, ,) (NP (NN beta-catenin)) (, ,) (NP (NN EGFR)) (, ,) (NP (NN CCND1) (NN gene)))) |ET| |BS|23:D12.776.091.249 359:G05.355.760.385 402:G05.360.340.024.340.375.500.791.148 403:C04.557.470.200.588 404:A03.556.500.760 405:V03.100 406:V03.100|ES| 2:1 9:1 19:1 60:1 104:1 187:1 304:1 417:1 643:1 661:1 862:1 934:1 936:1 1018:1 1025:1 1379:1 1380:1 1381:1 1382:1 1383:1 1384:1 1385:1
1 	|BT| (NP (NP (NP (JJ Mammary) (NN tumour)) (NP (VBN observed) (NN EphB4) (JJ transgenic) (NN animal))) (: ;) (NP (ADVP (RB however)) (, ,) (NP (NP (JJ double) (JJ transgenic) (NN animal) (VBG expressing) (NN EphB4) (NN neuT) (NN gene)) (, ,) (NP (NN tumour) (NN appearance)) (S (S (ADVP (RB significantly)) (VP (VBD accelerated))) (, ,) (NP (NP (NN contrast) (JJ neuT-only) (NN animal)) (, ,) (NP (NN metastasis)) (NP (VBD observed) (NN lung))))))) |ET| |BS|6:G05.360.340.024.340 8:C04 19:B01.050 113:C04.697.650 182:A04.411 352:B01.050.050.136 407:E01.370.225.812.735.550 408:C04.588.531|ES| 2:1 9:1 19:1 46:1 124:1 217:1 261:1 285:1 328:1 806:1 810:1 1011:1 1379:1 1386:1 1387:1 1388:1 1389:1 1390:1 1391:1 1392:1 1393:1
1 	|BT| (S (NP (JJ Maternal) (NN folate) (NN level) (NN polymorphism) (JJ folate-related) (NN gene)) (VP (VBN known) (NP (NP (NN risk) (NN factor) (JJ neural) (NN tube) (NN defect)) (PRN (-LRB- -LRB-) (NP (NNS NTDs)) (-RRB- -RRB-))))) |ET| |BS|6:G05.360.340.024.340 224:D03.438.733.631.400 307:G05.365.795 409:E05.318.740.600.800.725 410:F01.829.263.500.320.200 411:C10.500.680|ES| 9:1 10:1 14:1 19:1 171:1 185:1 249:1 556:1 588:1 778:1 1060:1 1394:1 1395:1 1396:1 1397:1 1398:1
1 	|BT| (S (NP (NNS METHODS) (: :)) (NP (NP (JJ Aberrant) (NN methylation) (NN status) (NN p16) (NN promoter) (NN region)) (, ,) (NP (NN expression) (NN product)) (, ,) (NP (NP (NN loss) (NN heterozygosity)) (PRN (-LRB- -LRB-) (NP (NN LOH)) (-RRB- -RRB-))) (NP (NN 9p21))) (VP (VBD examined) (NP (NP (NP (ADJP (RB surgically) (JJ resected)) (NN lung) (NN specimen) (CD 57) (NN patient)) (PRN (-LRB- -LRB-) (NP (CD 28) (JJ male) (CD 29) (NN female)) (-RRB- -RRB-))) (S (NP (JJ peripheral-type) (NN lung) (NN adenocarcinoma)) (VP (VBG measuring) (NP (ADVP (JJR <) (: /)) (NP (JJ =) (CD 2) (NN cm) (NN diameter)))))))) |ET| |BS|36:G02.111.087.029.538 50:M01.643 115:E04 168:E05.581 182:A04.411 196:G02.111.570.080.689.675 203:G05.360.340.024.340.375.249.375 228:E05.978 290:G05.365.590.029.530|ES| 2:1 10:1 14:1 19:1 32:1 80:1 81:1 83:1 104:1 115:1 120:1 148:1 255:1 312:1 324:1 326:1 328:1 416:1 528:1 565:1 667:1 675:1 1004:1 1154:1 1312:1 1313:1 1399:1 1400:1 1401:1 1402:1 1403:1 1404:1 1405:1 1406:1 1407:1 1408:1 1409:1
1 	|BT| (NP (NP (NN Methylation) (NN TFPI2) (NN stool) (NN DNA)) (: :) (NP (JJ potential) (JJ novel) (NN biomarker) (NN detection) (JJ colorectal) (NN cancer))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 36:G02.111.087.029.538 158:D23.101 198:D13.444.308 259:D12.776.395.240.150.500 355:A12.459|ES| 17:1 18:1 19:1 104:1 572:1 666:1 827:1 885:1 891:1 1023:1 1184:1 1185:1
1 	|BT| (S (NP (NNS Mutations) (NN EGFR) (NN gene)) (VP (VBD detected) (NP (NP (JJ pulmonary) (NN adenocarcinoma)) (PRN (-LRB- -LRB-) (NP (NNS ADCs)) (-RRB- -RRB-))))) |ET| |BS|18:G05.365.590 358:G05.360.340.024.340.375.500.791.295.300|ES| 9:1 10:1 14:1 19:1 187:1 255:1 948:1 1007:1 1410:1 1411:1
1 	|BT| (NP (NP (NNP New) (NN aspect) (JJ clinicopathologic) (NN oncogene) (NN study)) (NP (CD 23) (JJ pulmonary) (JJ lymphoepithelioma-like) (NN carcinoma))) |ET| |BS|9:G05.360.340.024.340.375.500 182:A04.411 265:C04.557.470.200|ES| 19:1 24:1 131:1 304:1 948:1 1412:1 1413:1 1414:1 1415:1 1416:1
1 	|BT| (S (NP (NN OBJECTIVE) (: :)) (VP (TO To) (VP (VB test) (SBAR (IN whether) (S (NP (NP (NP (JJ brain-targeted) (NN gene) (NN therapy) (JJ recombinant) (JJ adeno-associated) (NN virus)) (PRN (-LRB- -LRB-) (NP (NN rAAV5)) (-RRB- -RRB-))) (: -) (NP (NN IDUA) (NN vector) (NN MPS-I) (JJ transgenic) (NN mouse) (NN model))) (VP (MD would) (VP (VB reverse) (NP (JJ pathological) (NN hallmark))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 99:B01.050.050.136.500 367:A08.186.211 412:C16.320.565.202.715.640 413:B04.280.580.650.170 414:B04.280.580.650.170 415:F01.658.500 416:G05.360.337 417:H02.403.650|ES| 9:1 10:1 14:1 19:1 52:1 72:1 104:1 130:1 221:1 285:1 362:1 828:1 866:1 939:1 1417:1 1418:1 1419:1 1420:1 1421:1 1422:1 1423:1 1424:1 1425:1 1426:1 1427:1
1 	|BT| (NP (NP (NP (JJ Odd-skipped) (JJ related) (CD 1) (JJ novel) (NN tumour) (NN suppressor) (NN gene)) (JJ potential) (JJ prognostic) (NN biomarker) (JJ gastric) (NN cancer))) |ET| |BS|158:D23.101 206:G05.360.340.024.340.375.249 259:D12.776.395.240.150.500|ES| 9:1 18:1 19:1 86:1 98:1 419:1 700:1 827:1 884:1 885:1 891:1 1011:1 1428:1
1 	|BT| (S (PP (IN Of) (NP (JJ acidophilic) (NN lesion))) (PRN (, ,) (NP (NP (NP (NN majority) (NN focus)) (PRN (-LRB- -LRB-) (NP (NP (CD 28/32)) (, ,) (NP (CD 88) (NN %))) (-RRB- -RRB-))) (NN adenoma) (-LRB- -LRB-) (CD 47/50) (, ,) (NP (CD 94) (NN %))) (-RRB- -RRB-)) (VP (VBD expressed) (NP (NP (VBN increased) (NN bcl-X)) (PRN (-LRB- -LRB-) (NP (NN L)) (-RRB- -RRB-))) (, ,) (SBAR (IN whereas) (S (VP (VBN increased) (SBAR (S (NP (NN bcl-2)) (VP (VBN observed) (NP (NP (ADJP (CD 12.5) (NN %)) (JJ acidophilic) (JJ preneoplastic) (NN focus)) (PRN (-LRB- -LRB-) (NP (CD 4/32)) (-RRB- -RRB-))) (NP (NP (ADJP (CD 14) (NN %)) (JJ acidophilic) (NN adenoma)) (PRN (-LRB- -LRB-) (NP (CD 7/50)) (-RRB- -RRB-))))))))))) |ET| |BS|17:C04.557.470.035 54:G05.360.340.024.340.375.500.791.150 418:D12.644.360.075.718.937 419:C04.557.465.625.650.025|ES| 2:1 6:1 10:1 14:1 19:1 42:1 47:1 151:1 198:1 261:1 369:1 372:1 1131:1 1194:1 1429:1 1430:1 1431:1 1432:1 1433:1 1434:1 1435:1 1436:1 1437:1 1438:1 1439:1 1440:1 1441:1
1 	|BT| (SINV (PP (IN Of) (NP (JJ small-cell) (JJ heterogeneous) (JJ basophilic) (NN lesion))) (, ,) (CD 86) (VP (NN %) (VP (NN focus) (SBAR (S (-LRB- -LRB-) (S (S (NP (NP (QP (CD 31/36) (-RRB- -RRB-) (CD 85) (NN %)) (NN adenoma)) (PRN (-LRB- -LRB-) (NP (CD 35/41)) (-RRB- -RRB-))) (VP (VBD exhibited) (NP (NP (VBN increased) (NN bcl-2) (NN protein) (NN level)) (PP (VBN compared) (S (VP (VBG surrounding) (NP (JJ normal) (NNS hepatocytes)))))))) (, ,) (IN whereas) (S (NP (NP (NP (ADJP (CD 12.5) (NN %)) (NN focus)) (PRN (-LRB- -LRB-) (NP (CD 4/36)) (-RRB- -RRB-))) (ADJP (CD 12) (NN %)) (NN adenoma) (PRN (-LRB- -LRB-) (NP (CD 5/41)) (-RRB- -RRB-))) (VP (VBD exhibited) (NP (NP (NP (VBN increased) (NN bcl-X)) (PRN (-LRB- -LRB-) (NP (NN L)) (-RRB- -RRB-))) (NN level)))))))))) |ET| |BS|7:D12.776 17:C04.557.470.035 41:A11 54:G05.360.340.024.340.375.500.791.150 175:J01.897.280.500.269 262:A11.436.348 418:D12.644.360.075.718.937 420:A11.118.637.415.120 421:G05.365.331 422:N01|ES| 2:1 4:1 10:1 14:1 19:1 42:1 47:1 50:1 118:1 151:1 249:1 369:1 372:1 609:1 894:1 1120:1 1131:1 1429:1 1431:1 1435:1 1436:1 1437:1 1442:1 1443:1 1444:1 1445:1 1446:1 1447:1 1448:1 1449:1 1450:1 1451:1
1 	|BT| (S (ADVP (NP (CD One) (NN year)) (RB later)) (, ,) (NP (JJ intra-abdominal) (JJ metastatic) (NN tumor)) (VP (VBD detected) (ADJP (JJ resected)))) |ET| |BS|8:C04 9:G05.360.340.024.340.375.500 25:G02.111.570.080 26:G02.111.570.080 27:G02.111.570.080 30:Z01.058.290.190.800 31:D08.811.520.224.800 98:A10 113:C04.697.650 143:E01.370.225.500.607.512 158:D23.101 198:D13.444.308 303:C04.557.450.795 372:G05.360.340.024.340.137.232 423:A01.923.047.025 424:L01.143.506.423.557 425:G01.358.500.505.650 426:E01.370.350.515 427:C04.588.033 428:D27.720.233|ES| 2:1 7:1 9:1 19:1 68:1 118:1 127:1 272:1 337:1 344:1 534:1 654:1 666:1 806:1 833:1 965:1 1007:1 1021:1 1055:1 1250:1 1255:1 1327:1 1400:1 1452:1 1453:1 1454:1 1455:1 1456:1 1457:1 1458:1 1459:1 1460:1 1461:1 1462:1 1463:1 1464:1 1465:1 1466:1 1467:1
1 	|BT| (S (NP (PRP$ Our) (NNS data)) (ADVP (RB firmly)) (VP (VBP establish) (NP (JJ unique) (JJ oncogenic) (NN capability) (NN DNp73) (NN drive)) (ADVP (FW hepatocarcinogenesis) (FW vivo)) (, ,) (S (VP (VBG supporting) (NP (NN significance) (NN marker) (NN disease) (NN severity) (NN patient) (NN target) (NN cancer) (NN prevention)))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 66:F01.658.293 158:D23.101 279:D27.888.569.100 288:C23.550.288|ES| 2:1 18:1 19:1 120:1 160:1 181:1 220:1 378:1 534:1 557:1 658:1 793:1 900:1 953:1 998:1 1468:1 1469:1 1470:1 1471:1 1472:1 1473:1 1474:1
1 	|BT| (NP (NP (PRP$ Our) (S (VP (NN finding) (VP (VB identify) (NP (NN EphA1) (JJ potential) (JJ prognostic) (NN marker) (NN CRC))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 158:D23.101|ES| 19:1 245:1 534:1 658:1 827:1 832:1 884:1 927:1 994:1
1 	|BT| (S (NP (PRP$ Our) (NN finding)) (VP (VBP suggest) (SBAR (S (NP (JJ allelic) (NN loss) (NN FHIT) (NN gene)) (VP (MD may) (NP (VBN involved) (NN carcinogenesis) (JJ peripheral) (NN lung) (NN patient) (NN IPF))))))) |ET| |BS|6:G05.360.340.024.340 33:C04.697.098 50:M01.643 182:A04.411 276:C08.381.483.487.500 290:G05.365.590.029.530 337:C08.381.765|ES| 9:1 19:1 32:1 120:1 207:1 328:1 491:1 658:1 774:1 796:1 927:1 946:1 1122:1 1475:1 1476:1
1 	|BT| (S (NP (PRP$ Our) (NN observation)) (VP (VBP suggest) (SBAR (S (NP (NN KLLN)) (VP (MD might) (VP (VBN used) (NP (JJ potential) (JJ prognostic) (NN marker) (JJ novel) (NN therapy) (NN target) (NN breast) (NN carcinoma)))))))) |ET| |BS|52:E02 158:D23.101 259:D12.776.395.240.150.500 429:N04.761.559.590.900 430:E05.581.249|ES| 19:1 23:1 130:1 160:1 304:1 476:1 534:1 658:1 796:1 798:1 827:1 884:1 891:1 1477:1 1478:1
1 	|BT| (S (NP (PRP$ Our) (VBP result)) (VP (VBP indicate) (NP (S (NP (NN miR-9) (NN miR-197)) (VP (ADVP (RB specifically)) (VBP downregulate) (NP (NN MTHFD1L) (NN level) (NN HEK293) (NN MCF-7) (NN cell) (NN SNPrs7646)) (ADVP (RB significantly)) (VP (VBP affect) (NP (NP (NN miR-197) (NN binding) (NN affinity) (NN MTHFD1L) (CD 3)) ('' ') (NN UTR)) (, ,) (S (VP (VBG causing) (NP (NP (JJ efficient) (JJ posttranscriptional) (NN gene) (NN repression) (NN presence) (NN allele)) (VP (VBN associated)))))))) (NP (VBD increased) (NN risk) (NNS NTDs))))) |ET| |BS|6:G05.360.340.024.340 61:E05.318.740.600.800 77:G05.360.340.024.340.030 208:F01.393.821 252:F02.784.692.351 411:C10.500.680 431:D13.444.735.544.875 432:A11.251.210.190.630 433:F01.470.047|ES| 2:1 9:1 19:1 47:1 94:1 101:1 124:1 169:1 171:1 230:1 249:1 346:1 508:1 658:1 706:1 862:1 1279:1 1398:1 1479:1 1480:1 1481:1 1482:1 1483:1 1484:1 1485:1 1486:1 1487:1 1488:1 1489:1 1490:1 1491:1 1492:1 1493:1
1 	|BT| (NP (NP (PRP$ Our) (VP (VBP result) (S (NP (NN offer) (JJ preclinical) (NN rationale)) (VP (VBG warranting) (NP (NP (JJ clinical) (NN investigation)) (VP (VBG combining) (NP (NNS HDACi) (NN EGFR) (JJ HER2-targeted) (NN therapy) (NN CRC) (NN treatment))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 52:E02 63:G05.360.340.024.340.375.500.791.295.305 65:D08.811.913.696.620.682.725.400.009.400 225:E05.337|ES| 19:1 84:1 101:1 130:1 187:1 245:1 505:1 546:1 658:1 1042:1 1494:1 1495:1 1496:1 1497:1 1498:1 1499:1
1 	|BT| (NP (NP (NN Overactivation) (NN Wnt-beta-catenin) (NN signaling)) (, ,) (PP (VBG including) (NP (NP (NN beta-catenin-TCF) (NN target) (NN gene) (NN expression)) (, ,) (NP (NP (NN hallmark) (JJ colorectal) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN CRC)) (-RRB- -RRB-))) (NP (NN development))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 23:D12.776.091.249 105:G02.149.115.800.925 155:G05.355.310|ES| 2:1 9:1 10:1 14:1 17:1 18:1 19:1 35:1 115:1 160:1 195:1 245:1 561:1 1427:1 1500:1 1501:1 1502:1
1 	|BT| (NP (NP (NN P53) (NN gene) (JJ deficient) (NN mouse)) (SBAR (-LRB- -LRB-) (S (S (NP (NN p53) (PRN (: -) (: /) (: -) (-RRB- -RRB-))) (VP (VBD found) (ADVP (RB spontaneously)) (VP (VB develop) (NP (JJ malignant) (NN lymphoma) (NN hemangiosarcoma))))) (, ,) (IN whereas) (FRAG (NP (NN heterozygote)) (-LRB- -LRB-) (NP (NP (NP (NN p53)) (CC +) (: /) (: -) (-RRB- -RRB-) (NN mouse) (NN display) (JJ high) (NN incidence) (NN tumor) (JJ urinary) (NN bladder)) (VP (VBN treated) (NP (NN N-butyl-N) (: -) (-LRB- -LRB-) (NN 4-hydroxybutyl) (-RRB- -RRB-) (NN nitrosamine)))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 157:G05.380.383 176:C04.557.386 434:E05.318.308.985.525.375 435:C04.557.450.795.390 436:C04.588.945.947.960 437:D02.654.442|ES| 2:1 7:1 9:1 10:1 14:1 19:1 37:1 52:1 178:1 372:1 564:1 591:1 648:1 802:1 1033:1 1099:1 1503:1 1504:1 1505:1 1506:1 1507:1 1508:1 1509:1 1510:1 1511:1 1512:1 1513:1 1514:1
1 	|BT| (NP (NP (NN Pdcd4)) (S (-LRB- -LRB-) (NP (VBN programmed) (NP (NP (NN cell) (NN death) (CD 4) (-RRB- -RRB-) (NN gene)) (NN tumor) (NN suppressor) (NN expression))) (ADVP (RB frequently)) (VP (VBD down-regulated) (NP (NN tumor)) (, ,) (NP (NP (VBN considered) (JJ diagnostic) (JJ prognostic) (NN marker)) (NP (ADJP (RB well) (JJ promising)) (NN target) (JJ anti-cancer) (NN therapy)))))) |ET| |BS|6:G05.360.340.024.340 8:C04 39:G04.299.139.160 52:E02 142:I01.880.604 158:D23.101 206:G05.360.340.024.340.375.249 263:E01 351:A17.360|ES| 2:1 7:1 9:1 10:1 14:1 19:1 94:1 115:1 130:1 160:1 319:1 411:1 534:1 698:1 700:1 787:1 884:1 903:1 1061:1 1112:1 1283:1 1515:1 1516:1 1517:1
1 	|BT| (NP (NP (NP (NN Point) (NN mutation) (JJ K-ras) (NN gene)) (, ,) (VP (VBD found) (NP (NP (ADJP (QP (CD 10) (CD 30)) (NN %)) (NN lung) (NN adenocarcinoma)) (, ,) (NP (VBN regarded) (RB early) (NN event) (NN carcinogenesis)))))) |ET| |BS|12:Z01.542.049 30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 438:G05.365.590.675|ES| 2:1 9:1 19:1 34:1 37:1 205:1 207:1 255:1 328:1 369:1 1121:1 1128:1 1518:1 1519:1 1520:1 1521:1
1 	|BT| (NP (NP (NP (JJ Primary) (JJ renal) (NN neoplasm) (NN ASPL-TFE3) (NN gene) (NN fusion) (JJ alveolar) (JJ soft) (NN part) (NN sarcoma)) (: :) (S (NP (JJ distinctive) (NN tumor) (NN entity)) (ADVP (RB previously)) (VP (VBD included) (PP (IN among) (NP (JJ renal) (NN cell) (NN carcinoma) (NN child))) (ADVP (JJ adolescent)))))) |ET| |BS|8:C04 274:C04.588.945.947.535 295:C04.557.470.200.025.390 359:G05.355.760.385 439:C04.557.450.590.775 440:M01.060.057 441:M01.060.406|ES| 7:1 9:1 19:1 94:1 104:1 304:1 451:1 922:1 935:1 936:1 1117:1 1287:1 1372:1 1522:1 1523:1 1524:1 1525:1 1526:1 1527:1 1528:1 1529:1 1530:1
1 	|BT| (S (NP (NN PURPOSE) (: :)) (VP (VBG Activating) (NP (NP (NP (NP (JJ somatic) (NN mutation) (JJ epidermal) (NN growth) (NN factor) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN EGFR)) (-RRB- -RRB-))) (NN gene)) (ADJP (ADJP (JJ present)) (ADJP (JJ small))) (NN subset) (NN lung) (NN adenocarcinoma)))) |ET| |BS|18:G05.365.590 442:G05.360.340.024.340.375.500.791.295.300 443:G05.700.264|ES| 9:1 10:1 14:1 19:1 34:1 102:1 104:1 184:1 185:1 186:1 187:1 255:1 328:1 388:1 687:1 750:1 950:1 1285:1 1307:1
1 	|BT| (S (NP (VBN Reduced) (NN ING1b) (NN gene) (NN expression)) (VP (VBP play) (NP (NP (JJ important) (NN role)) (NN carcinogenesis) (JJ non-small) (NN cell) (NN lung) (NN cancer) (NN patient)))) |ET| |BS|12:Z01.542.049 15:F01.829.316.616 33:C04.697.098 50:M01.643 79:I03.450.642.693 110:C04.588.894.797.520.109.220.249 155:G05.355.310|ES| 9:1 18:1 19:1 31:1 94:1 115:1 120:1 207:1 238:1 328:1 694:1 902:1 1134:1 1531:1
1 	|BT| (S (NP (NNS RESULTS) (: :)) (NP (NN EGFR) (NN gene) (NN mutation)) (VP (VBD identified) (NP (NP (CD 13) (NN %)) (NP (JJ primary) (NN tumor))))) |ET| |BS|8:C04 18:G05.365.590 358:G05.360.340.024.340.375.500.791.295.300|ES| 7:1 9:1 19:1 34:1 104:1 187:1 344:1 369:1 623:1 710:1 1532:1
-1 	|BT| (S (NP (NP (DT A) (NP (NP (JJ genetic) (NN basis) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (JJ well-established) (JJ major) (NN signaling) (NN pathway)) (, ,) (NP (NP (NN p53)) (, ,) (NP (NN Wnt-signaling)) (, ,) (NP (NP (NP (VBG transforming) (NN growth) (NN factor-beta)) (PRN (-LRB- -LRB-) (NP (NN TGF-beta)) (-RRB- -RRB-))) (NN Ras) (NN pathway))) (, ,)) (VP (VBD identified) (NP (JJ essential) (NN HCC) (NN development)))) |ET| |BS|1:G05.360.340.024.340.375.500.791.550 2:G05.360.340.024.340.375.249.385 30:Z01.058.290.190.800 31:D08.811.520.224.800 69:G02.111.087.800 104:C04.557.470.200.025.255 126:G02.111.087.800 149:G05.360.340.024.340.364.875.890 503:D12.644.276.374.687|ES| 2:1 10:1 12:1 14:1 19:1 35:1 69:1 102:1 195:1 303:1 304:1 383:1 441:1 462:1 623:1 864:1 1140:1 1770:1 1771:1 1772:1 1773:1 1774:1 1775:1 1776:1
-1 	|BT| (NP (NP (NP (NN BACKGROUND)) (CC &) (NP (NNS AIMS))) (: :) (S (NP (NP (NN p53) (NNS Mutations)) (JJ common) (NP (JJ human) (JJ hepatocellular) (NN carcinoma)) (, ,) (NP (NN induction) (JJ hepatic) (NN p53) (NN expression))) (VP (VBP cause) (SBAR (S (NP (NN lysis)) (VP (VBD implanted) (NP (NN hepatoblastoma) (NN cell) (JJ chimeric) (NN mouse)))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 11:B01.050.150.900.649.865.635.505.500 18:G05.365.590 41:A11 55:B01.050.150.900.649.801.400.112.400.400 73:N05.715.350.200 104:C04.557.470.200.025.255 504:C04.557.435.380 505:B05.200|ES| 2:1 12:1 19:1 36:1 52:1 94:1 104:1 115:1 303:1 304:1 655:1 736:1 838:1 1046:1 1410:1 1777:1 1778:1 1779:1 1780:1 1781:1 1782:1 1783:1
-1 	|BT| (S (ADVP (RB Instead)) (, ,) (NP (NNS data)) (VP (VBD revealed) (NP (NP (NP (NN Skp2)) (VBN regulated) (NN Myc) (NN activity)) (, ,) (NP (JJ oncogenic) (JJ potential) (NN generation) (JJ hepatocellular) (NN carcinoma))))) |ET| |BS|104:C04.557.470.200.025.255 142:I01.880.604 279:D27.888.569.100 506:F01.829.263.315 507:D12.776.157.743|ES| 2:1 19:1 275:1 303:1 304:1 399:1 793:1 827:1 953:1 1664:1 1784:1 1785:1 1786:1 1787:1
-1 	|BT| (NP (NP (NP (NN Loss) (NN miR-122) (NN cause) (JJ chronic) (NN steatohepatitis)) (NP (JJ spontaneous) (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|73:N05.715.350.200 104:C04.557.470.200.025.255 508:C06.552.241|ES| 19:1 283:1 303:1 304:1 1779:1 1788:1 1789:1 1790:1 1791:1
-1 	|BT| (S (NP (NP (NNS Mice)) (VP (VBG lacking) (NP (NN MAT1A)))) (VP (VBD reduced) (NP (JJ hepatic) (NN S-adenosylmethionine) (NN content) (NN hyperplasia)) (ADVP (RB spontaneously)) (VP (VB develop) (NP (JJ nonalcoholic) (NN steatohepatitis))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 232:D02.886.030.676.180 509:C06.552.241.519 510:C23.550.444|ES| 19:1 376:1 452:1 583:1 648:1 838:1 1506:1 1791:1 1792:1 1793:1 1794:1 1795:1 1796:1
-1 	|BT| (S (NP (NP (NP (NN MicroRNA-122)) (PRN (-LRB- -LRB-) (NP (NN miR-122)) (-RRB- -RRB-))) (, ,) (NP (ADJP (RB highly) (JJ abundant)) (JJ liver-specific) (NN miRNA)) (, ,)) (VP (VBP act) (NP (NP (NN tumor) (NN suppressor) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))))) |ET| |BS|81:E02.095.465.425.400.330.050.400 104:C04.557.470.200.025.255 184:D13.150.650.319 206:G05.360.340.024.340.375.249 242:A03.620|ES| 2:1 7:1 10:1 14:1 19:1 246:1 303:1 304:1 441:1 626:1 700:1 840:1 1789:1 1797:1 1798:1 1799:1
-1 	|BT| (S (NP (NP (NP (NN Peroxisome) (JJ proliferator-activated) (NN receptor-gamma1)) (PRN (-LRB- -LRB-) (NP (NN PPARgamma1)) (-RRB- -RRB-))) (JJ important) (NN transcription) (NN factor)) (VP (VBN involved) (NP (NN atherosclerosis) (NN progression)))) |ET| |BS|16:C23.550.291.656 166:D12.776.930 511:C14.907.137.126.307 512:D12.776.826.239 513:C14.907.137.126|ES| 10:1 14:1 19:1 48:1 185:1 487:1 774:1 902:1 1800:1 1801:1 1802:1 1803:1 1804:1
-1 	|BT| (S (NP (NP (ADVP (RB Surprisingly)) (, ,) (VBN given) (VBN proposed) (NN role) (NN loss) (NN function) (NN mutation) (NN p53) (NN gene) (NN development)) (NP (JJ human) (JJ colorectal) (NN cancer)) (, ,)) (VP (VBD found) (NP (NP (NN evidence)) (PP (CC either) (NP (NP (NN increase) (NN rate) (NN adenoma) (NN formation) (NN APC)) (CC +) (: /) (: -) (, ,) (NP (NN p53) (: -)) (: /) (FRAG (: -) (NP (NP (NN animal)) (, ,) (NP (NP (VBD increased) (NN rate) (NN progression) (NN malignancy)) (VP (VBN compared) (NP (NP (NN APC)) (NP (CC +) (: /) (: -) (NN p53) (CC +) (FRAG (: /) (CC +) (NP (NN mouse)))))))))))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 3:C04.557.470.035.215.100 4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 11:B01.050.150.900.649.865.635.505.500 12:Z01.542.049 13:D01.339.387 14:F01.525 15:F01.829.316.616 16:C23.550.291.656 17:C04.557.470.035 18:G05.365.590 19:B01.050 20:G03.495|ES| 2:1 9:1 11:1 12:1 17:1 18:1 19:1 28:1 29:1 30:1 31:1 32:1 33:1 34:1 35:1 36:1 37:1 38:1 39:1 40:1 41:1 42:1 43:1 44:1 45:1 46:1 47:1 48:1 49:1 50:1 51:1 52:1
-1 	|BT| (S (NP (DT The) (NN Tg737) (NN gene)) (VP (VBD investigated) (NP (JJ gross) (NN alteration) (NN series) (NN rodent/human) (NN liver) (NN tumor) (JJ human) (JJ tumorigenic) (NN cell) (NN line)))) |ET| |BS|6:G05.360.340.024.340 55:B01.050.150.900.649.801.400.112.400.400 94:A11.251.210 514:B01.050.150.900.649.865 515:C04.588.274.623|ES| 7:1 9:1 19:1 36:1 94:1 264:1 403:1 691:1 836:1 951:1 1805:1 1806:1 1807:1 1808:1 1809:1
-1 	|BT| (S (NP (DT A) (NN Cox) (JJ proportional) (NN hazard) (NN model)) (VP (VBD showed) (NP (NP (NN IFITM3) (NN expression) (JJ independent) (JJ prognostic) (NN factor)) (NP (JJ disease-free) (NN survival) (NN patient) (NN colon) (NN cancer))))) |ET| |BS|12:Z01.542.049 50:M01.643 516:E05.318.740.500.700 517:E01.789.200|ES| 18:1 19:1 69:1 72:1 113:1 115:1 120:1 132:1 185:1 274:1 696:1 883:1 884:1 1810:1 1811:1 1812:1 1813:1
